NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone781-890-9989
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.09 million
Profitability
Miscellaneous
Employees42
Next Earnings Date1/23/2020 (Estimated)
OptionableNot Optionable
Neurometrix (NASDAQ:NURO) Frequently Asked Questions
What is Neurometrix's stock symbol?
Neurometrix trades on the NASDAQ under the ticker symbol "NURO."
When did Neurometrix's stock split? How did Neurometrix's stock split work?
Neurometrix shares reverse split before market open on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2017. An investor that had 100 shares of Neurometrix stock prior to the reverse split would have 13 shares after the split.
How were Neurometrix's earnings last quarter?
Neurometrix Inc (NASDAQ:NURO) announced its quarterly earnings results on Thursday, October, 17th. The medical device company reported ($0.14) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The medical device company earned $2.09 million during the quarter, compared to analysts' expectations of $3.94 million. Neurometrix had a negative net margin of 48.86% and a negative return on equity of 65.19%. View Neurometrix's Earnings History.
When is Neurometrix's next earnings date?
What price target have analysts set for NURO?
1 brokers have issued 1-year price targets for Neurometrix's stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Neurometrix's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 1,685.7% from the stock's current price. View Analyst Price Targets for Neurometrix.
What is the consensus analysts' recommendation for Neurometrix?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurometrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurometrix.
Has Neurometrix been receiving favorable news coverage?
Media stories about NURO stock have been trending extremely negative this week, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neurometrix earned a news impact score of -4.3 on InfoTrie's scale. They also assigned news stories about the medical device company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Neurometrix.
Are investors shorting Neurometrix?
Neurometrix saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 129,600 shares, a decrease of 12.6% from the August 30th total of 148,200 shares. Based on an average trading volume of 115,700 shares, the short-interest ratio is presently 1.1 days. Currently, 1.4% of the shares of the company are sold short. View Neurometrix's Current Options Chain.
Who are some of Neurometrix's key competitors?
Some companies that are related to Neurometrix include DarioHealth (DRIO), Obalon Therapeutics (OBLN), Dynatronics (DYNT), Avinger (AVGR), Valeritas (VLRX), Sintx Technologies (SINT), CELLECT BIOTECH/S (APOP), Invivo Therapeutics (NVIV), Cytori Therapeutics (CYTX), Encision (ECIA), Calmare Therapeutics (CTTC), Cytocore (MDIT), AdvanSource Biomaterials Corpration (ASNB), United American Healthcare (UAHC) and Regenicin (RGIN).
What other stocks do shareholders of Neurometrix own?
Who are Neurometrix's key executives?
Neurometrix's management team includes the folowing people:
- Dr. Shai N. Gozani, Founder, Chairman, CEO, Pres & Sec. (Age 54)
- Mr. Thomas T. Higgins, Sr. VP, CFO & Treasurer (Age 67)
- Mr. Francis X. McGillin, Sr. VP & Chief Commercial Officer (Age 58)
- Mr. Michael J. MacDonald, Sr. VP of Commercial Operations & GM of Diagnostics
- Dr. Xuan Kong Ph.D., Chief Data Scientist
How do I buy shares of Neurometrix?
Shares of NURO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Neurometrix's stock price today?
One share of NURO stock can currently be purchased for approximately $0.28.
How big of a company is Neurometrix?
What is Neurometrix's official website?
How can I contact Neurometrix?
Neurometrix's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The medical device company can be reached via phone at 781-890-9989 or via email at [email protected]
MarketBeat Community Rating for Neurometrix (NASDAQ NURO)
MarketBeat's community ratings are surveys of what our community members think about Neurometrix and other stocks. Vote "Outperform" if you believe NURO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NURO will underperform the S&P 500 over the long term. You may vote once every thirty days.
